GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (FRA:CZTA) » Definitions » EPS (Diluted)

Checkpoint Therapeutics (FRA:CZTA) EPS (Diluted) : €-1.34 (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Checkpoint Therapeutics EPS (Diluted)?

Checkpoint Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was €-0.66. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.34.

Checkpoint Therapeutics's EPS (Basic) for the three months ended in Dec. 2024 was €-0.66. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.34.

Checkpoint Therapeutics's EPS without NRI for the three months ended in Dec. 2024 was €-0.66. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.34.

During the past 3 years, the average EPS without NRIGrowth Rate was 42.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 22.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Checkpoint Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 42.50% per year. The lowest was -32.10% per year. And the median was 12.40% per year.


Checkpoint Therapeutics EPS (Diluted) Historical Data

The historical data trend for Checkpoint Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics EPS (Diluted) Chart

Checkpoint Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.37 -6.59 -6.69 -2.91 -1.36

Checkpoint Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.01 -0.30 -0.17 -0.21 -0.66

Competitive Comparison of Checkpoint Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Checkpoint Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkpoint Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's PE Ratio falls into.


;
;

Checkpoint Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Checkpoint Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2024 is calculated as

Diluted EPS (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-53.709-0)/39.674
=-1.35

Checkpoint Therapeutics's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as

Diluted EPS (Q: Dec. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-27.6-0)/46.027
=-0.60

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Checkpoint Therapeutics  (FRA:CZTA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Checkpoint Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkpoint Therapeutics Business Description

Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics Headlines

No Headlines